Oncology Publications

The publications listed below are offered for informational purposes only and do not represent all publications to which X4 Pharmaceuticals or its collaboration partners have contributed or may contribute or that relate to X4 Pharmaceuticals’ product candidates. These publications are made available by third parties, and the content of any linked third-party site is the responsibility of the third party, not X4 Pharmaceuticals, and X4 Pharmaceuticals disclaims liability for the linked content.

Waldenstrom’s

Journal of Clinical Oncology, 38(11), 1198-1208. doi:10.1200/jco.19.02314

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Steven P. Treon, MD, PhD^1,2; Lian Xu, MS¹; Maria Luisa Guerrera, MD^1,2; Cristina Jimenez, PhD^1,2; Zachary R. Hunter, PhD^1,2; Xia Liu, MD^1,2; Maria Demos, BS¹; Joshua Gustine, MPH¹; Gloria Chan, MS¹; Manit Munshi, MS¹; Nicholas Tsakmaklis, BA¹; Jiaji G. Chen, BS¹; Amanda Kofides, BS¹; Romanos Sklavenitis-Pistofidis, MD^2,3,4; Mark Bustoros, MD^2,3; Andrew Keezer, BS¹; Kirsten Meid, MPH¹; Christopher J. Patterson, MAcc, MPH¹; Antonio Sacco, RN^3,4; Aldo Roccaro, MD, PhD⁴; Andrew R. Branagan, MD⁵; Guang Yang, PhD^1,2; Irene M. Ghobrial, MD^2,3; and Jorge J. Castillo, MD^1,2

Expert Rev Hematol. 2019 Jul 30:1-9. doi: 10.1080/17474086.2019.1649132. [Epub ahead of print]

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ¹, Moreno DF², Arbelaez MI³, Hunter ZR¹, Treon SP¹.

Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16088. [Epub ahead of print]

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Castillo JJ1,2, Xu L1, Gustine JN1,3, Keezer A1, Meid K1, Dubeau TE1, Liu X1, Demos MG1, Kofides A1, Tsakmaklis N1, Chen JG1, Munshi M1, Guerrera ML1, Chan GG1, Patterson CJ1, Yang G1,2, Hunter ZR1, Treon SP1,2.

Br J Haematol. 2015 Mar;168(5):701-7. doi: 10.1111/bjh.13200. Epub 2014 Nov 5.

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.

Cao Y¹, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP.

Leukemia. 2015 Jan;29(1):169-76. doi: 10.1038/leu.2014.187. Epub 2014 Jun 10.

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia.

Blood. 2014 Jun 26;123(26):4120-31. doi: 10.1182/blood-2014-03-564583. Epub 2014 Apr 7.

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Roccaro AM¹, Sacco A¹, Jimenez C², Maiso P¹, Moschetta M¹, Mishima Y¹, Aljawai Y¹, Sahin I¹, Kuhne M³, Cardarelli P³, Cohen L⁴, San Miguel JF⁵, Garcia-Sanz R², Ghobrial IM¹.

Author information

CXCR4 General: Tumor Microenvironment

Clin Cancer Res. 2015 Oct 1;21(19):4278-85. doi: 10.1158/1078-0432.CCR-14-0914. Epub 2015 Jul 21.

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment.

Renal

Oncotarget. 2017 Aug 19;8(44):77110-77120. doi: 10.18632/oncotarget.20363. eCollection 2017 Sep 29.

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.

Santagata S¹, Napolitano M¹, D’Alterio C¹, Desicato S², Maro SD³, Marinelli L³, Fragale A⁴, Buoncervello M⁴, Persico F⁵, Gabriele L⁴, Novellino E³, Longo N⁵, Pignata S², Perdonà S², Scala S¹.

Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D’ Alterio C¹, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Author information

Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori “Pascale”, Naples, Italy.

Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S¹, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Author information

Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Nature. 2003 Sep 18;425(6955):307-11.

Oncology Publications

Waldenstrom’s

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ¹, Moreno DF², Arbelaez MI³, Hunter ZR¹, Treon SP¹.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Castillo JJ1,2, Xu L1, Gustine JN1,3, Keezer A1, Meid K1, Dubeau TE1, Liu X1, Demos MG1, Kofides A1, Tsakmaklis N1, Chen JG1, Munshi M1, Guerrera ML1, Chan GG1, Patterson CJ1, Yang G1,2, Hunter ZR1, Treon SP1,2.

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.

Cao Y¹, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP.

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia.

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Roccaro AM¹, Sacco A¹, Jimenez C², Maiso P¹, Moschetta M¹, Mishima Y¹, Aljawai Y¹, Sahin I¹, Kuhne M³, Cardarelli P³, Cohen L⁴, San Miguel JF⁵, Garcia-Sanz R², Ghobrial IM¹.

Author information

CXCR4 General: Tumor Microenvironment

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment.

Renal

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.

Santagata S¹, Napolitano M¹, D’Alterio C¹, Desicato S², Maro SD³, Marinelli L³, Fragale A⁴, Buoncervello M⁴, Persico F⁵, Gabriele L⁴, Novellino E³, Longo N⁵, Pignata S², Perdonà S², Scala S¹.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D’ Alterio C¹, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Author information

Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori “Pascale”, Naples, Italy.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S¹, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Author information

Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Staller P¹, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W.

Oncology Publications

Waldenstrom’s

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

Castillo JJ1, Moreno DF2, Arbelaez MI3, Hunter ZR1, Treon SP1.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Castillo JJ1,2, Xu L1, Gustine JN1,3, Keezer A1, Meid K1, Dubeau TE1, Liu X1, Demos MG1, Kofides A1, Tsakmaklis N1, Chen JG1, Munshi M1, Guerrera ML1, Chan GG1, Patterson CJ1, Yang G1,2, Hunter ZR1, Treon SP1,2.

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.

Cao Y1, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP.

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia.

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Roccaro AM1, Sacco A1, Jimenez C2, Maiso P1, Moschetta M1, Mishima Y1, Aljawai Y1, Sahin I1, Kuhne M3, Cardarelli P3, Cohen L4, San Miguel JF5, Garcia-Sanz R2, Ghobrial IM1.

Author information

CXCR4 General: Tumor Microenvironment

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment.

Renal

Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.

Santagata S1, Napolitano M1, D’Alterio C1, Desicato S2, Maro SD3, Marinelli L3, Fragale A4, Buoncervello M4, Persico F5, Gabriele L4, Novellino E3, Longo N5, Pignata S2, Perdonà S2, Scala S1.

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

D’ Alterio C1, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Author information

Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori “Pascale”, Naples, Italy.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S1, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Author information

Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Staller P1, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W.

Castillo JJ¹, Moreno DF², Arbelaez MI³, Hunter ZR¹, Treon SP¹.

Cao Y¹, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP.

Roccaro AM¹, Sacco A¹, Jimenez C², Maiso P¹, Moschetta M¹, Mishima Y¹, Aljawai Y¹, Sahin I¹, Kuhne M³, Cardarelli P³, Cohen L⁴, San Miguel JF⁵, Garcia-Sanz R², Ghobrial IM¹.

Santagata S¹, Napolitano M¹, D’Alterio C¹, Desicato S², Maro SD³, Marinelli L³, Fragale A⁴, Buoncervello M⁴, Persico F⁵, Gabriele L⁴, Novellino E³, Longo N⁵, Pignata S², Perdonà S², Scala S¹.

D’ Alterio C¹, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.

Vanharanta S¹, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Staller P¹, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W.